Skip to main content
James Harding, MD, Oncology, New York, NY

JamesHardingMD

Oncology New York, NY

Gastrointestinal Cancer

Associate Attending and Member, Gastrointestinal Oncology Service, Early Drug Development Service, Memorial Sloan Kettering Cancer Center

Overview of Dr. Harding

Dr. James J. Harding is an oncologist in New York, NY and is affiliated with Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College. He specializes in Gastrointestinal Cancer with a clinical and research focus on liver and biliary tract cancers.

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2007 - 2010
  • Albert Einstein College of Medicine
    Albert Einstein College of MedicineClass of 2007

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2008 - 2026
  • NJ State Medical License
    NJ State Medical License 2019 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Nivolumab (NIVO) and drug eluting bead transarterial chemoembolization (deb-TACE): Preliminary results from a phase I study of patients (pts) with liver limited hepato... 
    ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
  • A phase II randomized placebo-controlled study investigating the combination of yiv-906 and sorafenib (SORA) in HBV (+) patients (Pts) with advanced hepatocellular car... 
    ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
  • ADI-PEG 20 and FOLFOX6: A phase 1 study in pts (pts) with advanced hepatocellular carcinoma (HCC). 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

  • FDA Approves Zanidatamab for Biliary Tract Cancer
    FDA Approves Zanidatamab for Biliary Tract CancerNovember 21st, 2024
  • Treatment Options for Advanced HCC Patients Who Are Not Eligible for IO First Line
    Treatment Options for Advanced HCC Patients Who Are Not Eligible for IO First LineMarch 14th, 2023
  • Puma Biotechnology Presents Interim Results from the Biliary Tract Cohort of Its Phase II SUMMIT Basket Trial of Neratinib at the ESMO World Congress on Gastrointestinal Cancer 2019
    Puma Biotechnology Presents Interim Results from the Biliary Tract Cohort of Its Phase II SUMMIT Basket Trial of Neratinib at the ESMO World Congress on Gastrointestinal Cancer 2019July 3rd, 2019
  • Join now to see all

Professional Memberships